CG
EPZM

Cutler Group’s Epizyme, Inc EPZM Stock Holding History

Cutler Group’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,800
Closed -$1K – 6662
2021
Q2 		$1K Buy
+2,800
New +$23.6K ﹤0.01% 5529
2018
Q3 		– Sell
-3,000
Closed -$2K – 4915
2018
Q2 		$2K Buy
3,000
+500
+20% +$7.78K ﹤0.01% 3685
2018
Q1 		$3K Buy
2,500
+400
+19% +$6.76K ﹤0.01% 3656
2017
Q4 		$1K Sell
2,100
-9,500
-82% -$138K ﹤0.01% 4667
2017
Q3 		$30K Sell
11,600
-5,700
-33% -$87K ﹤0.01% 2751
2017
Q2 		$18K Buy
17,300
+11,100
+179% +$168K ﹤0.01% 3546
2017
Q1 		$24K Sell
6,200
-19,800
-76% -$264K ﹤0.01% 3159
2016
Q4 		$27K Buy
+26,000
New +$271K ﹤0.01% 3169

Other funds holding EPZM

Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Cutler Group's EPZM Position: Q3 2022 in Review

Cutler Group sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 2,400 shares — an estimated $3K sold.

Cutler Group first reported a position in EPZM in Q4 2015 and held it in 20 quarters. The position peaked at $116K in Q2 2017. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.

  • Cutler Group reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 2,400 Epizyme, Inc shares in Q3 2022, an estimated $3K.
  • Cutler Group first reported a position in Epizyme, Inc in Q4 2015 and held it in 20 quarters.
  • Cutler Group's Epizyme, Inc position peaked at $116K in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.